RESUMO
Atopic dermatitis (AD) pathogenesis is strongly influenced by Type 2 innate lymphoid cell and T-helper cell type 2 lymphocyte-driven inflammation and skin barrier dysfunction. AD therapies attempt to correct this pathology, and guidelines suggest suggest basics of AD therapy, which include repair of the skin barrier through bathing practices and moisturizers, infection control, and further lifestyle modifications to avoid and reduce AD triggers.While some patients' AD may be controlled using these measures, inflammatory eczema including acute flares and maintenance therapy in more severe patients are treated with topical pharmacologic agents such as topical corticosteroids, topical calcineurin inhibitors, and, more recently, topical PDE-4 inhibitors. This model of basic skin therapy and, as needed, topical pharmacologic agents may be used to treat the vast majority of patients with AD and remains the staple of AD therapy.
Assuntos
Dermatite Atópica/tratamento farmacológico , Administração Cutânea , Corticosteroides/administração & dosagem , Corticosteroides/efeitos adversos , Antibacterianos/administração & dosagem , Banhos/métodos , Inibidores de Calcineurina/administração & dosagem , Vestuário , Alcatrão/administração & dosagem , Dermatite Atópica/terapia , Emolientes/administração & dosagem , Antagonistas dos Receptores Histamínicos/administração & dosagem , Humanos , Ceratolíticos/administração & dosagem , Inibidores da Fosfodiesterase 4/administração & dosagem , Creme para a Pele/administração & dosagemRESUMO
Atopic dermatitis (AD) is a complex condition that results from the dynamic interplay between genetic predisposition, skin barrier defects, environmental factors, and a dysfunctional immune system. As a result, AD can be complicated by irritant and allergic contact dermatitis and imbalances in the skin microbiome, which can subsequently exacerbate the severity and complicate the course of preexisting atopic disease. Itch is an important symptom of AD, as it plays a large role in the quality of life of patients and their families. Since AD is a chronic, inflammatory disease that recrudesces throughout life, many have utilized alternative and/or complementary therapies, as monotherapy or in conjunction with conventional therapies, as a form of management.